Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations



Status:Enrolling by invitation
Healthy:No
Age Range:18 - 80
Updated:4/21/2016
Start Date:April 2014
End Date:June 2016

Use our guide to learn which trials are right for you!

Pilot Study on the Response of Inherited Erythromelalgia Patients With NaV1.7 Mutations to Carbamazepine: Clinical Imaging Study

This research study is designed to investigate brain response using fMRI scan, and
behavioral responses, to treatment with the drug carbamazepine (CBZ) in patients with the
painful sodium channelopathy inherited Erythromelalgia (IEM). This study is designed to
identify the central nervous system (CNS) regions that are activated during ongoing or
evoked pain attacks, and the altered CNS response to CBZ treatment. This will advance our
understanding of how IEM affects the brain. We also hope to validate a pharmacogenic
approach to the study of IEM by use of an FDA approved drug. We hope, but cannot be sure,
that subjects will directly benefit from this study.


Inclusion Criteria:

- diagnosis/symptoms of EM

- specific NaV1.7 sodium channel mutations (including S241T)

Exclusion Criteria:

- patients with no identified NaV1.7 mutation
We found this trial at
2
sites
950 Campbell Ave
West Haven, Connecticut 06516
(203) 932-5711
VA Connecticut Healthcare System VA Connecticut encompasses an inpatient facility and Ambulatory Care Center in...
?
mi
from
West Haven, CT
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials